Introduction and objective In this study, we evaluated the influence of the transcript type on hematological and clinical parameters, as well as the event-free survival of 50 patients in the Chronic myeloid leukemia chronic phase. Methods We reviewed the medical records of 55 patients with Chronic myeloid leukemia. The eligibility criteria were based on the availability of hematological and clinical baseline data in the medical records. Data on BCR-ABL transcripts were obtained from medical records. Results Eighteen patients (36%) had the b2a2 transcript, 24 (48%) had b3a2 and 8 (16%) had b2a2/b3a2 . The median platelet count for transcripts b2a2 , b3a2 and b2a2/b3a2 was 320.65 × 10 3 /L, 396 × 10 3 /L, and 327.05 × 10 3 /L, respectively ( p = 0.896). We could not find any differences in relation to the other hematological parameters, when compared to the transcript type. Comparison between spleen and liver size and type of transcript did not differ inside the groups ( p = 0.395 and p = 0.647, respectively) and the association between risk scores and transcript type did not show statistical significance ( p > 0.05). The 21-month probability for event-free survival was 21%, 48% and 66% for the transcripts b2a2 , b3a2 and b2a2/b3a2 respectively ( p = 0.226) Conclusion We conclude that the expression BCR-ABL transcripts have no influence on hematological, clinical and event-free survival parameters of patients in the Chronic myeloid leukemia chronic phase.

No abstract

O‐Acylamidoxime and 1,2,4‐oxadiazole derivatives were synthesized from adamantanecarbonyl chloride 1 and a diversity of arylamidoximes 2 a‐k. First, O‐acylamidoximes intermediates 3 a‐k were synthesized and subsequent cyclization under microwave irradiation afforded 1,2,4‐oxadiazol derivatives 4 a‐k. Molar Heat of Reaction Calorimetry studies performed from O‐acylamidoximes revealed influence of the substituent groups. A one‐pot two‐step methodology was also developed proving to be a viable protocol. Compounds were characterized by 1H and 13C Nuclear Magnetic Resonance (NMR) Spectroscopy, Elemental Analysis or High Resolution Mass Spectral Analysis, and subjected to cytotoxic studies in non‐tumoral Vero cells and antiproliferative activity tests in six malignant cell lines. Our findings suggest that compounds 3 derivatives presented a concentration‐dependent profile for chronic myeloid leukemia (K562) and acute promyelocytic leukemia (HL‐60) cell.

The aim of the study was to investigate the association between oxidative stress and DNA damage with grafting time in patients submitted to autologous hematopoietic stem-cell transplantation (HSCT). The study included 37 patients submitted to autologous HSCT diagnosed with Multiple Myeloma (MM) and lymphoma (Hodgkin’s and non-Hodgkin’s). Biomarkers of oxidative stress and DNA damage index (DI) were performed at baseline (pre-CR) of the disease and during the conditioning regimen (CR), one day after the HSCT, ten days after HSCT and twenty days after HSCT, as well as in the control group consisting of 30 healthy individuals. The outcomes showed that both groups of patients had an hyperoxidative state with high DI when compared to baseline and to the control group and that the CR exacerbated this condition. However, after the follow-up period of the study, this picture was re-established to the baseline levels of each pathology. The study patients with MM showed a mean grafting time of 10.75 days (8 to 13 days), with 10.15 days (8 to 15 days) for the lymphoma patients. In patients with MM, there was a negative correlation between the grafting time and the basal levels of GPx (r = -0.54; p = 0.034), indicating that lower levels of this important enzyme are associated with a longer grafting time. For the DI, the correlation was a positive one (r = 0.529; p = 0.030). In the group with lymphoma, it was observed that the basal levels of NOx were positively correlated with grafting time (r = 0.4664, p = 0.032). The data indicate the potential of these biomarkers as predictors of toxicity and grafting time in patients with MM and Lymphomas submitted to autologous HSCT.

O transtorno do espectro autista (TEA) é um transtorno do neurodesenvolvimento cujas alterações comportamentaispodem ser investigadas por meio de modelos animais de TEA e pela realização  de testes comportamentais para avaliação das alterações. O objetivo deste trabalho foi realizar uma pesquisa bibliográfica sobre os modelos comportamentais animais que têm sido utilizados para o estudo do TEA e a correlação desses modelos com o comportamento humano no TEA. Para esta pesquisa bibliográfica, foi conduzida uma busca nas bases de dados Medline, Web of Science e Clinical Key, no período de junho a setembro de 2019, por artigos científicos na temática de estudo, sendo selecionados artigos publicados entre os anos de 2006 e 2019. No estudo experimental do TEA, são conduzidos testes comportamentais em animais considerando as características clínicas e manifestações do transtorno. Estes modelos experimentais são utilizados para a avaliação do potencial indutor de substâncias para o desenvolvimento do TEA, como para a avaliação de potenciais fármacos ou terapias não farmacológicas para o tratamento do transtorno. Os testes mais comumente utilizados são: teste de campo aberto, teste de enterramento de esferas de vidro, teste de interação social, teste do comportamento repetitivo de autolimpeza, teste do labirinto em cruz elevado, teste de habituação olfativa e odores sociais e teste claro-escuro. Reitera-se a importância desses testes em modelos in vivo de estudo do TEA, possibilitando uma maior compreensão das alterações comportamentais e um melhor entendimento desse transtorno.